PRTC news & sentiment — PureTech Health plc

APR 22·Stock TitanHigh

Complete responses put PureTech's LYT-200 deeper into blood cancer trials

PureTech announced positive topline data from its Phase 1b trial of LYT-200 for relapsed/refractory high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML), showing complete responses and favorable tolerability. The company plans to prioritize R/R HR-MDS for further development and engage with the FDA for a potential registration-supporting trial. LYT-200, an anti-galectin-9 monoclonal antibody, demonstrated robust antileukemic activity, including a 45.5% overall response rate in HR-MDS patients.

DEC 8·Investing.com

PureTech stock falls after FDA meeting on IPF drug

PureTech Health PLC (NASDAQ:PRTC) stock dropped in premarket trading after the company received FDA feedback supporting advancement for its idiopathic pulmonary fibrosis (IPF) drug, deupirfenidone, into a pivotal Phase 3 trial. Despite the positive regulatory path, investor concern arose over the timeline, as the Phase 3 trial is not expected to start until the first half of 2026. The new trial aims for potential registration via a 505(b)(2) pathway, building on promising Phase 2b results.

DEC 8·BioPharma Dive

PureTech launches new biotech built around lung disease drug

PureTech Health has launched Celea Therapeutics, a new biotech company focused on developing a respiratory disease treatment. Celea Therapeutics will advance deupirfenidone (LYT-100), an improved version of pirfenidone, for idiopathic pulmonary fibrosis and other inflammatory lung diseases. The drug has shown positive results in a Phase 2b trial and is moving toward Phase 3 discussions with the FDA.

$PRTC

Complete responses put PureTech's LYT-200 deeper into blood cancer trials

PureTech stock falls after FDA meeting on IPF drug

PureTech launches new biotech built around lung disease drug

News on $PRTC